Skinvisible, Inc. (SKVI)

Our latest clients all have the potential to grow significantly in the near and long-term future

Skinvisible, Inc. (SKVI)

Postby QualityStocks » Thu Oct 05, 2017 7:31 pm

Skinvisible, Inc., through its wholly owned subsidiary Skinvisible Pharmaceuticals, Inc., is a Research and Development company whose patented Invisicare® technology can be used to revitalize or create new medical or skincare products, allowing a company that licenses Skinvisible’s formulations to sell their own patented product and combat generic competitors.

A prescription dermatology product can generate $100 million or more a year, with the potential to lose 50-90% of that revenue when it goes off patent. Preserving that revenue is why the licensing of a product made with Invisicare is a very desirable option for many companies. The Company has developed a pipeline of 40 products using Invisicare, with a primary focus on optimizing the performance and increasing the value of “gold standard” dermatology drugs and licensing them to international and multi-national companies in the pharmaceutical, over-the-counter and cosmeceutical markets.

Invisicare® is a high performance topical and transdermal delivery system which enhances the delivery of drugs and other ingredients to and through the skin. The key to Skinvisible’s patented technology and trademarked Invisicare® family of polymer delivery vehicles is its formula and process for combining hydrophilic and hydrophobic polymers into stable complexes in water emulsions. Invisicare® can be a key component of life cycle management, extending the life with a new patent-protected product, dramatically expanding the company’s revenue stream.

Independent studies of Invisicare ® have shown the following benefits:

- Active ingredients stay on the skin for up to four hours or more and resist wash off and rub off.
- Delivery method results in improved efficacy, reduced skin irritation and lower required dosage.
- Unique formulations are non-drying and provide the ability to control the release of active ingredients.
- Products form a protective barrier, which means normal skin respiration and perspiration occur and the product wears off as part of the skin’s natural exfoliation process.

Terry Howlett, President, founder and CEO of Skinvisible Inc., said the Company has more than 15 years of scientific research and product development experience. All development is conducted using stringent pharmaceutical standards. The Company has licensed a number of its formulations including a prescription hemorrhoid cream in the USA, its anti-aging Kintari® line of products and DermSafe®, its non-alcohol hand sanitizer to a licensee in China. Producing licensed products for the booming cannabis industry is also an important element of the company’s business strategy.

Skinvisible’s foray into the rapidly expanding market for medicinal and recreational cannabis products is already underway with the development of the company’s first hemp-derived CBD (cannabidiol) products. Skinvisible has negotiated an exclusive licensing deal in Canada with Canopy Growth Corporation, one of the world’s leading cannabis companies. As part of the company’s overall growth strategy, Skinvisible is also negotiating with a Licensed Producer in Las Vegas where Skinvisible scientists will develop THC (tetrahydrocannabinol) products for the legal recreational and medical marijuana market for the USA. Notably, Skinvisible is actively pursuing potential licensees through-out the world where medical cannabis is legal. These licensees will have the exclusive right to manufacture and distribute Skinvisible’s cannabis products within their territory.

“We are excited about the results we are already seeing just with our hemp-derived CBD products,” Howlett says. “Our science shows that our CBD products release almost four times that of market leaders and our transdermal product had an 81% penetration rate at 6 hours. These results are significant and provide the difference between ordinary cannabis products and ones enhanced by Invisicare.”

The Company’s business model includes out-licensing its formulations for a development fee, license fee and on-going royalties in addition to selling its Invisicare polymers to its licensees.
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 760
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Skinvisible, Inc. (SKVI)

Postby QualityStocks » Fri Oct 06, 2017 3:50 pm

Skinvisible, Inc. (SKVI) is “One to Watch”

- Patented technology enhances how topical and transdermal drugs and skin care products are delivered
- Polymer delivery vehicle can be tailored to almost any type of molecule including the medicinal components of hemp and marijuana
- 14 patents granted in the U.S. and internationally
- $65 billion market in dermatology, pharmaceutical and other healthcare industries offers strong growth opportunity

Skinvisible, Inc. (OTCQB: SKVI), through its wholly owned subsidiary Skinvisible Pharmaceuticals, Inc., is a Research and Development company whose patented Invisicare® technology can be used to revitalize or create new medical or skincare products, allowing a company that licenses Skinvisible’s formulations to sell their own patented product and combat generic competitors.

A prescription dermatology product can generate $100 million or more a year, with the potential to lose 50-90% of that revenue when it goes off patent. Preserving that revenue is why the licensing of a product made with Invisicare is a very desirable option for many companies. The Company has developed a pipeline of 40 products using Invisicare, with a primary focus on optimizing the performance and increasing the value of “gold standard” dermatology drugs and licensing them to international and multi-national companies in the pharmaceutical, over-the-counter and cosmeceutical markets.

Invisicare® is a high performance topical and transdermal delivery system which enhances the delivery of drugs and other ingredients to and through the skin. The key to Skinvisible’s patented technology and trademarked Invisicare® family of polymer delivery vehicles is its formula and process for combining hydrophilic and hydrophobic polymers into stable complexes in water emulsions. Invisicare® can be a key component of life cycle management, extending the life with a new patent-protected product, dramatically expanding the company’s revenue stream.

Independent studies of Invisicare ® have shown the following benefits:

Active ingredients stay on the skin for up to four hours or more and resist wash off and rub off.
Delivery method results in improved efficacy, reduced skin irritation and lower required dosage.
Unique formulations are non-drying and provide the ability to control the release of active ingredients.
Products form a protective barrier, which means normal skin respiration and perspiration occur and the product wears off as part of the skin’s natural exfoliation process.
Terry Howlett, President, founder and CEO of Skinvisible Inc., said the Company has more than 15 years of scientific research and product development experience. All development is conducted using stringent pharmaceutical standards. The Company has licensed a number of its formulations including a prescription hemorrhoid cream in the USA, its anti-aging Kintari® line of products and DermSafe®, its non-alcohol hand sanitizer to a licensee in China. Producing licensed products for the booming cannabis industry is also an important element of the company’s business strategy.

Skinvisible’s foray into the rapidly expanding market for medicinal and recreational cannabis products is already underway with the development of the company’s first hemp-derived CBD (cannabidiol) products. Skinvisible has negotiated an exclusive licensing deal in Canada with Canopy Growth Corporation, one of the world’s leading cannabis companies. As part of the company’s overall growth strategy, Skinvisible is also negotiating with a Licensed Producer in Las Vegas where Skinvisible scientists will develop THC (tetrahydrocannabinol) products for the legal recreational and medical marijuana market for the USA. Notably, Skinvisible is actively pursuing potential licensees through-out the world where medical cannabis is legal. These licensees will have the exclusive right to manufacture and distribute Skinvisible’s cannabis products within their territory.

“We are excited about the results we are already seeing just with our hemp-derived CBD products,” Howlett says. “Our science shows that our CBD products release almost four times that of market leaders and our transdermal product had an 81% penetration rate at 6 hours. These results are significant and provide the difference between ordinary cannabis products and ones enhanced by Invisicare.”

The Company’s business model includes out-licensing its formulations for a development fee, license fee and on-going royalties in addition to selling its Invisicare polymers to its licensees.

For more information, visit the company’s website at www.Skinvisible.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 760
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Skinvisible, Inc. (SKVI)

Postby QualityStocks » Thu Oct 12, 2017 6:17 pm

NetworkNewsBreaks – Why Skinvisible, Inc. (SKVI) is Worth Watching in a $65B Market

Skinvisible, Inc. (OTCQB: SKVI), through its wholly owned subsidiary Skinvisible Pharmaceuticals, Inc., is an R&D company offering its patented Invisicare® technology, which can be used to revitalize or create new medical or skincare products, thus enabling companies that license Skinvisible’s formulations to sell their own patented products and ward off generic rivals. A high-performance topical and transdermal delivery system, Invisicare enhances the delivery of drugs and other ingredients to and through the skin utilizing Skinvisible’s innovative formula and process for combining hydrophilic and hydrophobic polymers into stable complexes in water emulsions. An article discussing this reads: “A prescription dermatology product can generate $100 million or more a year, with the potential to lose 50-90% of that revenue when it goes off patent. Preserving that revenue is why the licensing of a product made with Invisicare is a very desirable option for many companies. The Company has developed a pipeline of 40 products using Invisicare, with a primary focus on optimizing the performance and increasing the value of ‘gold standard’ dermatology drugs and licensing them to international and multi-national companies in the pharmaceutical, over-the-counter and cosmeceutical markets.”
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 760
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Skinvisible, Inc. (SKVI)

Postby QualityStocks » Mon Oct 16, 2017 4:36 pm

Skinvisible, Inc. (SKVI) Has Been Delivering its Patented Polymer Technology to Pharmaceuticals & Cosmeceuticals for Close to Two Decades

- Topical product technology protected by patents
- Targeting $80 billion global skin care and dermatology market
- Product sales in China

Outsourcing has been the status quo in the pharmaceutical industry since long before the term gained notoriety. Large pharmaceutical and cosmeceutical companies, under pressure from rising R&D costs, have been farming out that part of their businesses for a long time now in an attempt to reduce costs. This approach also has the advantage of offloading the costs of patenting to the outsourcee. To obtain the advantages of adopting new technology, patent protection is vital to avoid copycatting. That is why the technology developed by Skinvisible, Inc. (OTCQB: SKVI), through its wholly owned subsidiary Skinvisible Pharmaceuticals, Inc., has been adopted by pharmaceutical and cosmeceutical companies since 1999. The Las Vegas, Nevada–based R&D company developed Invisicare® technology, which can be used to revitalize or create new medical or skin care products, allowing a company that licenses Skinvisible’s formulations to sell their own patented product and combat generic competitors.

Invisicare is a patented polymer delivery system that improves the delivery of topically applied skin care products, thereby enhancing the efficacy of the active ingredients. The unique process extends the time the product remains active on the skin and is specifically formulated to transport active ingredients that are insoluble in water without using alcohol, silicones, waxes, or other organic solvents.

Products utilizing Invisicare have been effective at bonding active ingredients to the skin for up to four hours and longer. Invisicare is non-occlusive; it allows normal skin respiration and perspiration while moisturizing and protecting against exposure from a wide variety of environmental irritants. When topically applied, products formulated with Invisicare adhere to the skin’s outer layers, forming a protective bond, resisting wash-off, and delivering targeted levels of therapeutic or cosmetic skin care agents to the skin. This allows enhanced delivery performance for a variety of topicals, resulting in improved efficacy, longer duration of action, reduced irritation and lower dosage of active agent required. The “invisible” polymer compositions that make up Invisicare wear off as part of the natural exfoliation process that removes the skin’s outer layer of cells.

With a $80 billion global dermatology market and a $30 billion global skin care over-the-counter (OTC) market, the patented polymer delivery system for topical products developed by Skinvisible, obviously, has many, many possible applications. The company has already inked an agreement (http://nnw.fm/a1Izk) with a large, well-known Canadian medical marijuana company: the first to attain ‘unicorn’ status in the industry. Under the agreement, the MMJ company will distribute Skinvisible’s topical products in Canada. The agreement covers two distinct product lines made with Skinvisible’s Invisicare technology. Skinvisible will develop unique topical hemp-based products to be launched by Canopy Hemp Corporation in Canada and the United States. In addition, the agreement includes potential cannabis-based topical products using Invisicare® technology when and if federal regulations permit CBD- or THC-infused topical products for sale in Canada.

While it continues to expand its licensing relationships, Skinvisible is developing its own line of OTC products, which is available for out-licensing. The 40+ products include antimicrobial hand sanitizers and skin care products for acne, skin fungi and atopic dermatitis. Skinvisible has also developed its own line of anti-aging products under the Kintari® brand (day cream, night cream, hand & body lotion, sunscreen and DermSafe), all available on www.Kintari.com. Kintari is a wholly owned subsidiary of Skinvisible.

In June 2017, the company announced that it had completed its first international sale of DermSafe® hand sanitizer in China (http://nnw.fm/awjI5) through its agent, InterSpace Global, Inc. The agreement with InterSpace Global facilitates the export of Skinvisible’s OTC products to mainland China, Hong Kong, Macau, Taiwan, Singapore, Malaysia, Thailand and Korea. In the beauty-conscious Chinese diaspora, Skinvisible is on track to repeat its U.S. success story.

For more information, visit the company’s website at www.Skinvisible.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 760
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ


Return to QualityStocks Featured Companies

Who is online

Users browsing this forum: No registered users and 2 guests

cron